« Return to News | Drug Sponsors

Par to acquire Anchen for $410 million

Thursday, August 25, 2011 11:17 AM

Generics drug maker Par Pharmaceutical has reached an agreement to acquire privately-held Anchen Pharmaceuticals, according to PharmaTimes.

Par is prepared to part with $410 million in cash to get hold of Anchen, which specializes in extended-release and niche generics. It has five commercialized products, 27 Abbreviated New Drug Applications pending with the FDA and 26 additional products in development.

Anchen anticipates launching eight-ten niche generic products over the next two years. The Irvine, California-headquartered firm has 218 employees "and over 72,000 square feet of expandable manufacturing and warehouse facilities with state-of-the-art equipment."

Par chief executive Patrick LePore said that Anchen has "an excellent development track record and robust product pipeline, which, when combined with Par's existing capabilities and pipeline, more than doubles our product opportunities.”

The transaction is expected to be immediately accretive to earnings in 2011 and Par noted that it will finance the deal with the help of a $350 million term loan.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.